December 5, 2025 – Talk Bio

Recent news on Biopharma Sentiment Index (BPSI)

2 months ago talkbio0Tagged Attitude, Biopharma, Biopharma Sentiment Index, BPSI, drug development sentiment, Endpoints, investing, News [Publication Type], Pharma Industry, Sentiment

Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook

Recent news on ACIP’s hepatitis B birth‑dose recommendation

2 months ago talkbio0Tagged ACIP, birth dose, Centers for Disease Control and Prevention (U.S.), Clinical Decision-Making, Hepatitis B, hepatitis B policy change, Immunization Schedule, Infant, pregnancy screening, Vaccination

ACIP; hepatitis B; birth dose; infant vaccination; shared clinical decision-making; CDC immunization schedule; pregnancy screening; hepatitis B policy change

Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

2 months ago talkbio0Tagged clinical seizure, Epilepsy, focal onset seizures, meeting, Phase 2a Trial, Phase 3 trials, RAP-219, Rapport Therapeutics, seizure drug, United States Food and Drug Administration

Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

2 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, cryo-EM, generative biology, high-throughput protein production, manufacturability, mini-proteins, molecular glues, next-generation biologics, PROTACs, protein degraders, protein design, Protein Engineering, Structural Biology

next-generation biologics; protein engineering; bispecific antibodies; antibody-drug conjugates (ADCs); protein degraders; PROTACs; molecular glues; mini-proteins; AI in protein design; manufacturability; structural biology; cryo-EM; high-throughput protein production; generative biology

UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance

2 months ago talkbio0Tagged AMT-130, antibody collaboration, AstraZeneca, biopharmaceutical partnerships, external control group, Feedback - system communication, gene therapy, Nerve Degeneration, Neurimmune, UniQure, United States Food and Drug Administration

UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships

Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies

2 months ago talkbio0Tagged Antibodies, Bispecific, China, CR-001, Crescent Biopharma, Kelun-Biotech, Licensing, oncology partnership, PD-1xVEGF, Reciprocal, SKB105, therapeutic autologous dendritic cells

Crescent Biopharma; Kelun-Biotech; PD-1xVEGF; CR-001; SKB105; reciprocal licensing; oncology partnership; China; ADC; bispecific antibody